We envision a world where all people receive the best level of medical and pharmaceutical care regardless of who they are or where they live. Our focus is to support providers and patients in the US with beneficial medications, and to donate profits to the ROW Foundation. ROW seeks to improve the education, diagnosis, and treatment available for those living with neurological disorders in under-resourced areas of the world.
In short, OWP uses commercial success for the common good by supporting humanitarian projects in many countries. OWP offers three Starter Kits (Orange, Blue, and Green), each based on FDA-approved 5-week titration schedules, for patients initiating lamotrigine therapy. Cases of lifethreatening serious rashes, including StevensJohnson syndrome and toxic epidermal necrolysis, and/or rashrelated death have been caused by lamotrigine.
In short, OWP uses commercial success for the common good by supporting humanitarian projects in many countries. OWP offers three Starter Kits (Orange, Blue, and Green), each based on FDA-approved 5-week titration schedules, for patients initiating lamotrigine therapy. Cases of lifethreatening serious rashes, including StevensJohnson syndrome and toxic epidermal necrolysis, and/or rashrelated death have been caused by lamotrigine.
Reviews (1)
Reenie Martin Meyer
Aug 09, 2019
Report
Pharmaceutical Social Enterprise (is this an oxymoron?) OWP uses commercial success for the common good by supporting humanitarian projects rather than maximizing profits. Wow! ....a pharmaceutical company that uses their US profits to provide life saving drugs to less advantaged countries in the world!
